Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea
Unknown statusNot applicableNCT01070277
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Study hypotheses is that Antiparasitic therapy in patients with chronic diarrhea after travel to a developing country, with a negative stool findings, will be significantly effective in eliminating diarrhea and other gastro-intestinal complaints compared to similar patients receiving placebo.
Study details
- Conditions
- Chronic Diarrhea
- Abdominal Pain
- Bloating
- Interventions
- Drug: Tinidazole and Albendazole
- Drug: Placebo control
- Sponsor
- Sheba Medical Center
- Start date
- 2012-03
- Primary completion
- 2015-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Israel
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diarrhea (3 or more soft stools per day) for at least two weeks after a trip to a developing country in the past year * Stool sample negative for bacteria, parasites and helminthes at least once * Has not received, until now, antiparasitic or antihelminthic therapy Exclusion Criteria: * Bloody diarrhea * Fever during enrolment 5. Allergy to the offered medication
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01070277